Biotricity Inc. (Biotricity) today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023. The company reported that the Q1-FY24 revenue grew by 46.9% YOY to $3.0 million, continuing to advance toward positive cashflow.
Biotricity Inc. (Biotricity) today reported a strong start to its Fiscal Year 2024 ending March 31, 2024 and provided a preliminary estimate of its revenue for its first quarter of fiscal year 2024. For the first fiscal quarter ended June 30, 2023, the Company expects to report an approximate increase in revenue which represents growth of over 40% YOY from the corresponding prior year quarter and expects to achieve continued reduction in expenses.
Biotricity Inc. (Biotricity) reported that it reached a record $12 million annualized revenue run rate in March 2023. Based on preliminary month-to-date results and internal projections, the Company remains excited regarding potential top line revenue growth in April and the current quarter (Q4FY23) as it maintains optimized investment in R&D, sales and marketing. The Company attributed its strengthening financials to the growing sales of its product line of remote cardiac monitors spanning consumers to cardiologists, the ramp up of its subscription-based recurring service revenues, and the early success of its recently expanded distribution strategy.
Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its third quarter of fiscal 2023 ended December 31, 2022. Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “With our suite of state-of-the-art remote cardiac solutions now well established, Biotricity is focused on sales, marketing and achieving positive cash flow.”
Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.
Wedge Networks Inc. (Wedge), a global leader in software defined Orchestrated Real-time Threat Prevention, is pleased to announce its 2021 Audited Consolidated Financial Statements have been released and are now available to shareholders.
Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks.”
Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2022 fourth quarter and year ended March 31, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “Fiscal 2022 was a pivotal year for Biotricity as we made significant strides in our product development and commercialization strategy.
